Boston—Elderly patients with cardiovascular comorbidities were at the greatest risk for having a variant of drug-metabolizing enzymes (DMEs) and predicted to gain the most benefit from pharmacogenomics (PGx) risk screening during a study by investigators from University of Utah Health Care (UUHC).
“Polypharmacy is common among elderly patients and carries a high risk of adverse drug events—overdose toxicity and drug treatment failure—as a result of